Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Suzhou Alphamab Co. Ltd. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, so each pending matter is associated with a separate examination path in the available record.
CANELLA, KAREN A is the busiest examiner, with 1 pending matter. Prosecution planning should account for three separate examiner relationships rather than treating the portfolio as a single examination stream.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANELLA, KAREN A | 1 | 62.3% | +32.8% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.1% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270097 | HUMAN GLP-1 POLYPEPTIDE VARIANT AND USE THEREOF | NIEBAUER, RONALD T | 60d |
| 18691672 | COMPOSITION COMPRISING PD-L1 ANTIGEN-BINDING FRAGMENT AND USE THEREOF | CANELLA, KAREN A | — |
| 18014318 | COAGULATION FACTOR XI (FXI) BINDING PROTEIN | DAHLE, CHUN WU | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1641 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18691672 | COMPOSITION COMPRISING PD-L1 ANTIGEN-BINDING FRAGMENT AND USE THEREOF | CANELLA, KAREN A | 1643 | §102§103§112DP | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18014318 | COAGULATION FACTOR XI (FXI) BINDING PROTEIN | DAHLE, CHUN WU | 1641 | §102§112DP | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18270097 | HUMAN GLP-1 POLYPEPTIDE VARIANT AND USE THEREOF | NIEBAUER, RONALD T | 1658 | §103§112DP | Final Rejection | 60d | Pending | Jun 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSuzhou Alphamab Co. Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Karen A Canella has the most, with 1 of Suzhou Alphamab Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
